Berlin Cures Holding AG is pioneering the development of aptamer-based therapeutics, specifically focusing on their lead compound, BC 007. This innovative drug is designed to selectively neutralize pathogenic functional autoantibodies (fAABs) that are implicated in various debilitating diseases, including heart failure and Long COVID. The company's technology platform utilizes DNA aptamers, which are short, single-stranded DNA molecules that can bind to specific target molecules with high specificity, similar to antibodies. BC 007 has shown promising results in clinical studies, demonstrating significant improvements in heart function and symptom relief in patients suffering from Long COVID, with a long-lasting neutralization effect of over 12 months.

The therapeutic approach of Berlin Cures addresses the underlying causes of diseases associated with fAABs, offering a unique modality that could revolutionize treatment options for conditions that currently lack effective therapies. The company is advancing its clinical pipeline, with ongoing Phase II studies for both heart failure and Long COVID, and plans to explore additional indications where fAABs play a critical role. By leveraging their proprietary bioassay for detecting fAABs, Berlin Cures aims to provide personalized treatment options, enhancing the efficacy and safety of their therapeutics in addressing complex health challenges.

Germany

Berlin Cures was first to follow up on the scientific finding that there are a large number of diseases associated with pathological functional autoantibodies directed against G protein-couples receptors. Heart failure and Long Covid belong to this group of diseases. Our aptamer BC 007 can neutralize these autoantibodies and this is the reason why Berlin Cures has been working for decades to develop a product based on scientific findings that may help many suffering patients.

Berlin Cures Holding AG

Company Details